Quantitative evaluation of the effects of acetazolamide in Friedreich's ataxia: a pilot study.
We evaluated the effects of acetazolamide in 4 young patients with Friedreich's ataxia by clinical and quantitative laboratory methods. Dynamic muscle function of the lower extremity was measured during isokinetic knee movements and gait. The acetazolamide trial was terminated at 7 to 11 weeks because of reported side effects or increased ataxia in 3 of the patients. The quantitative evaluations revealed lower dynamic strength values and alterations in the gait movement pattern in all patients. These changes, which were interpreted as deterioration, were partially reversible with cessation of acetazolamide. The advantages of such quantitative evaluations of dynamic muscle function in the evaluation of therapy in Friedreich's ataxia are discussed.
D000086:Acetazolamide / Q000627:therapeutic use*; D000293:Adolescent; D002648:Child; D004341:Drug Evaluation; D004576:Electromyography; D005260:Female; D005621:Friedreich Ataxia / Q000188:drug therapy* / Q000503:physiopathology; D005684:Gait; D006801:Humans; D008297:Male; D009132:Muscles / Q000503:physiopathology
D000086:Acetazolamide